Kimberley Rubino, PA
Physician Assistant · Bronx, NYNPI 1760962328
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,525 of the $29,044 with a category attached, or 67.2%. AbbVie accounts for 76.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $11,276 and has fallen 55.5% since, to $5,014 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $66.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$764
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$685
- Otsuka America Pharmaceutical, Inc.$619
- Corium, LLC$482
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$19,52567%
- Travel & lodging$4662%
- Food & beverage$9,01431%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 133 | $22,226 |
| Johnson & Johnson | 48 | $1,115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $764 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $685 |
| Otsuka America Pharmaceutical, Inc. | 28 | $619 |
| Corium, LLC | 25 | $482 |
| Neurocrine Biosciences, Inc. | 17 | $389 |
| Supernus Pharmaceuticals, Inc. | 20 | $367 |
| Alkermes, Inc. | 16 | $335 |
| Axsome Therapeutics, Inc. | 8 | $287 |
| Lundbeck LLC | 14 | $276 |
| Vanda Pharmaceuticals Inc. | 11 | $248 |
| Sunovion Pharmaceuticals Inc. | 10 | $232 |
| Bausch Health US, LLC | 10 | $213 |
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
| Avanir Pharmaceuticals, Inc. | 5 | $128 |
| Almatica Pharma LLC | 3 | $66 |
| Tempus AI, Inc | 3 | $64 |
| Eisai Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Neos Therapeutics, LP | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,044 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 119 | $141,231 |
| Aripiprazole | 20 | $1,337 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $635 |
| Bupropion XlBupropion Hcl | 41 | $387 |
| Duloxetine Hcl | 18 | $259 |
| Clonazepam | 23 | $204 |
| Mirtazapine | 20 | $186 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $176 |
| Lamotrigine | 19 | $146 |
| Gabapentin | 18 | $133 |
| Trazodone Hcl | 16 | $113 |
| Alprazolam | 17 | $50 |
| Lithium Carbonate | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,115 | $141,231119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Bronx
- Henry YuBronx$1M
- Julius NwosuBronx$256K
- George LopezBronx$46K
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.